Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus vaccine quadrivalent - Seqirus

Next Previous
Drug Profile

Influenza virus vaccine quadrivalent - Seqirus

Alternative Names: Adjuvanted quadrivalent influenza vaccine - Seqirus; Adjuvanted quadrivalent influenza vaccine surface antigen inactivated - Seqirus; Adjuvanted quadrivalent subunit influenza virus vaccine - Seqirus; aIIV-B - Seqirus; aIIV-C - Seqirus; aQII; aQIV - Seqirus; aQIVc - Seqirus; Cell based quadrivalent subunit influenza virus vaccine - Seqirus; FLUAD QUADRIVALENT; Fluad Tetra; IIV-A - Seqirus; MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine; MF59 adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine - Seqirus; MF59-Adjuvanted influenza vaccine - Seqirus; MF59-Adjuvanted quadrivalent subunit inactivated Influenza Vaccine - Seqirus; MF59® - Adjuvanted seasonal influenza vaccine - Seqirus; Subunit inactivated influenza vaccine - Seqirus

Latest Information Update: 21 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; Seqirus
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 03 Nov 2023 Phase-III clinical trials in Influenza virus infections (Prevention) in Denmark (IM) (NCT06015282)
  • 29 Aug 2023 Seqirus plans a phase III (Celljuvant Study) trial in Influenza virus infections (Prevention) (IM) in October 2023 (NCT06015282)
  • 31 Mar 2023 Seqirus completes a phase II trial for Influenza virus infections (Prevention, In adults, In the elderly) USA (IM) (NCT05501561)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top